Riskpilot← Back to searchSign inGet full accessPerfusion Tech ApS
APSActiveCVR 38238213Viborggade 70D, 1.Research and experimental development on natural sciences and engineering · NACE 7210Est. 201610 employeesperfusiontech.com
Revenue 2024
DKK -9M
+67% vs 2023
EBITDA margin
181.7%
-53% vs 2023
Equity ratio
37.8%
Financial strength
Net profit 2024
DKK -14,5M
-52% vs 2023
| Revenue | DKK -9M | +67% |
| EBITDA | DKK -16,4M | -53% |
| Net profit | DKK -14,5M | -52% |
| Total assets | DKK 5,6M | -37% |
| Equity | DKK 2,1M | -26% |
| Employees | 10 | — |
Legal name
Perfusion Tech ApS
CVR number
38238213
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28. november 2016
Share capital
DKK 118.457
Employees
10 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med et bestyrelsesmedlem eller af den samlede bestyrelse i forening.
Company purpose
Selskabet har til formål at udvikle, markedsføre og kommercialisere medicinsk udstyr, herunder ved gennemførelse af forsknings- og udviklingsaktiviteter, og andre hermed relaterede aktiviteter.
Address
Viborggade 70D, 1.
Email
contact@perfusiontech.com
Website
perfusiontech.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -278 | -262 | -539 | -1.092 | -1.067 | -4.201 | -5.414 | -9.022 |
| Staff expenses | -0 | -0 | -58 | -526 | -1.346 | -3.362 | -5.292 | -7.373 |
| EBITDA | -278 | -262 | -597 | -1.618 | -2.413 | -7.563 | -10.706 | -16.395 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -7 |
| EBIT | -278 | -262 | -597 | -1.618 | -2.413 | -7.563 | -10.706 | -16.402 |
| Net financials | -6 | -44 | -63 | -94 | -280 | -270 | -306 | -289 |
| Profit before tax | -284 | -305 | -660 | -1.712 | -2.693 | -7.833 | -11.013 | -16.691 |
| Tax | -13 | -67 | -64 | -227 | -575 | -1.277 | -1.468 | -2.221 |
| Net profit | -272 | -238 | -596 | -1.486 | -2.118 | -6.556 | -9.545 | -14.470 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 311 | 471 | 622 | 686 | 1.264 | 4.888 | 8.832 | 5.585 |
| Equity | -214 | -453 | -329 | -1.815 | -3.932 | 1.170 | 2.873 | 2.114 |
| Long-term debt | 291 | 758 | 819 | 1.442 | 4.575 | 3.116 | 2.972 | 1.501 |
| Short-term debt | 234 | 165 | 132 | 1.058 | 622 | 602 | 2.987 | 1.970 |
| Total debt | 526 | 923 | 951 | 2.501 | 5.197 | 3.718 | 5.959 | 3.471 |
EBITDA margin
-1639483400.0%
This company
15.8%
Market median
-10376477315% vs market
20172024
Equity ratio
37.8%
This company
38.2%
Market median
+1% vs market
20172024
Return on equity
-684.4%
This company
18.4%
Market median
-3820% vs market
20172024
Net profit margin
-1446952000.0%
This company
8.1%
Market median
-17863605038% vs market
20172024
Asset turnover
-1.62×
This company
1.12×
Market median
-245% vs market
20172024
Debt / equity
1.64×
This company
0.62×
Market median
-165% vs market
20172024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2016-11-28 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DC Management | Management | 2025 | — | — |
MA Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
PC Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Chairman | 2017 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2025 | |
TJ Biotech Holding ApS | Company | 5.0% | 5.0% | 2023 |
Uddannelses- og Forskningsstyrelsen | Company | 5.0% | 5.0% | 2023 |
ASBA CONSULTING ApS | Company | 15.0% | 15.0% | 2016 |
TJ BIOTECH HOLDING ApS | Company | 10.0% | 10.0% | 2019 |
Quantass ApS | Company | 5.0% | 5.0% | 2024 |
QUANTASS ApS | Company | 10.0% | 10.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Perfusion Tech ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Declan Cassells | Management | 0 companies |
| Mads Aagaard Linde Madsen | Chief Executive Officer | 0 companies |
| Pernille Charlotte Singer | Chief Executive Officer | 0 companies |
| Lars Henning Stigel | Board of Directors | 0 companies |
| Sten Scheibye | Board of Directors | 0 companies |
| Henrik Christensen | Chairman | 0 companies |
| Jeppe Øvli Øvlesen | Board of Directors | 0 companies |
| Steffen Boutrup Møller | Board of Directors | 0 companies |
| Thomas Engelbrecht Nordkild Jonassen | Board of Directors | 0 companies |
| Morten Asp Vonsild Lund | Chairman | 0 companies |